Literature DB >> 3501613

Complement and dengue haemorrhagic fever/shock syndrome.

P Malasit1.   

Abstract

The complement system is activated in DHF/DSS. The peak of activation and the presence of C3a and C5a anaphylatoxins coincided with the onset of shock and leakage. The levels of C3a correlated well with disease severity. This indicated an important role of the complement system in the pathogenesis of shock. Circulating immune complexes as assayed by two standard techniques were not detected in the majority of patients, and if detected were found in small amount. The role of circulating immune complexes in the activation of complement in DHF/DSS needs to be reinvestigated, and other possible mechanisms leading to complement activation should be sought.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3501613

Source DB:  PubMed          Journal:  Southeast Asian J Trop Med Public Health        ISSN: 0125-1562            Impact factor:   0.267


  34 in total

Review 1.  Dengue: defining protective versus pathologic immunity.

Authors:  Alan L Rothman
Journal:  J Clin Invest       Date:  2004-04       Impact factor: 14.808

Review 2.  Dengue: a continuing global threat.

Authors:  Maria G Guzman; Scott B Halstead; Harvey Artsob; Philippe Buchy; Jeremy Farrar; Duane J Gubler; Elizabeth Hunsperger; Axel Kroeger; Harold S Margolis; Eric Martínez; Michael B Nathan; Jose Luis Pelegrino; Cameron Simmons; Sutee Yoksan; Rosanna W Peeling
Journal:  Nat Rev Microbiol       Date:  2010-12       Impact factor: 60.633

3.  Differentially expressed genes of human microvascular endothelial cells in response to anti-dengue virus NS1 antibodies by suppression subtractive hybridization.

Authors:  Yue Yin; Lan Jiang; Danyun Fang; Lifang Jiang; Junmei Zhou
Journal:  Viral Immunol       Date:  2013-05-22       Impact factor: 2.257

Review 4.  Endothelial cells in dengue hemorrhagic fever.

Authors:  Anon Srikiatkhachorn; James F Kelley
Journal:  Antiviral Res       Date:  2014-07-12       Impact factor: 5.970

Review 5.  Immunity to dengue virus: a tale of original antigenic sin and tropical cytokine storms.

Authors:  Alan L Rothman
Journal:  Nat Rev Immunol       Date:  2011-07-15       Impact factor: 53.106

6.  Conserved MHC class I-presented dengue virus epitopes identified by immunoproteomics analysis are targets for cross-serotype reactive T-cell response.

Authors:  James S Testa; Vivekananda Shetty; Gomathinayagam Sinnathamby; Zacharie Nickens; Julie Hafner; Shivali Kamal; Xianchao Zhang; Marti Jett; Ramila Philip
Journal:  J Infect Dis       Date:  2012-01-13       Impact factor: 5.226

7.  Dengue fever as a rare cause of pulmonary embolism.

Authors:  Francesco Poletto; Lorenzo Cerruti; Luca Spiezia
Journal:  J Thromb Thrombolysis       Date:  2020-05       Impact factor: 2.300

8.  Dengue Virus Induces Increased Activity of the Complement Alternative Pathway in Infected Cells.

Authors:  Sheila Cabezas; Gustavo Bracho; Amanda L Aloia; Penelope J Adamson; Claudine S Bonder; Justine R Smith; David L Gordon; Jillian M Carr
Journal:  J Virol       Date:  2018-06-29       Impact factor: 5.103

Review 9.  Dengue vaccines: recent developments, ongoing challenges and current candidates.

Authors:  Monica A McArthur; Marcelo B Sztein; Robert Edelman
Journal:  Expert Rev Vaccines       Date:  2013-08       Impact factor: 5.217

Review 10.  Complement and its role in protection and pathogenesis of flavivirus infections.

Authors:  Panisadee Avirutnan; Erin Mehlhop; Michael S Diamond
Journal:  Vaccine       Date:  2008-12-30       Impact factor: 3.641

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.